The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.

Key facts

Study ID

NCT01843855

Run by

Adrian Vella

People needed

12

Starts

2011-06-01

Expected to finish

2013-09-01

Last updated by the study team

2013-12-04

Who can join

Age: 20 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of > 110 mg/dL
• Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).

You may not qualify if…

• Subjects taking thiazolidinediones
• Subjects with active systemic illness
• Subjects with active microvascular or macrovascular complications of their diabetes
• For female subject: positive pregnancy test at the time of enrollment in study

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.